[go: up one dir, main page]

CL2008002692A1 - Uso de una composicion a base de bayas de goji o una parte de la misma para preparar un producto util para tratar o prevenir la inflamacion. - Google Patents

Uso de una composicion a base de bayas de goji o una parte de la misma para preparar un producto util para tratar o prevenir la inflamacion.

Info

Publication number
CL2008002692A1
CL2008002692A1 CL2008002692A CL2008002692A CL2008002692A1 CL 2008002692 A1 CL2008002692 A1 CL 2008002692A1 CL 2008002692 A CL2008002692 A CL 2008002692A CL 2008002692 A CL2008002692 A CL 2008002692A CL 2008002692 A1 CL2008002692 A1 CL 2008002692A1
Authority
CL
Chile
Prior art keywords
prepare
treat
composition based
useful product
prevent inflammation
Prior art date
Application number
CL2008002692A
Other languages
English (en)
Inventor
David Philippe
Karine Vidal
Stephanie Blum-Sperisen
Olivier Dallevre
Peter Bucheli
Junkuan Wang
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of CL2008002692A1 publication Critical patent/CL2008002692A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A61K36/815—Lycium (desert-thorn)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)

Abstract

Uso de una composición a base de bayas de goji o una parte de la misma para preparar un producto útil para tratar o prevenir la inflamación.
CL2008002692A 2007-09-12 2008-09-10 Uso de una composicion a base de bayas de goji o una parte de la misma para preparar un producto util para tratar o prevenir la inflamacion. CL2008002692A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07116190A EP2036568A1 (en) 2007-09-12 2007-09-12 Wolfberries and inflammation

Publications (1)

Publication Number Publication Date
CL2008002692A1 true CL2008002692A1 (es) 2009-10-16

Family

ID=38984201

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008002692A CL2008002692A1 (es) 2007-09-12 2008-09-10 Uso de una composicion a base de bayas de goji o una parte de la misma para preparar un producto util para tratar o prevenir la inflamacion.

Country Status (15)

Country Link
US (2) US20100303741A1 (es)
EP (3) EP2036568A1 (es)
JP (1) JP2010540415A (es)
CN (2) CN103417728A (es)
AR (1) AR068448A1 (es)
AU (1) AU2008297074A1 (es)
BR (1) BRPI0816789A2 (es)
CA (2) CA2699233C (es)
CL (1) CL2008002692A1 (es)
ES (1) ES2698199T3 (es)
MX (1) MX2010002499A (es)
PT (1) PT2200624T (es)
RU (1) RU2499604C2 (es)
TW (1) TW200930389A (es)
WO (2) WO2009034165A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201021821A (en) * 2008-12-10 2010-06-16 Fl Dauern Res Inc Formulations and methods for maintaining normal levels of catecholamines, glucocorticoids, androsteroids and their related hormones
EP2473180A2 (en) * 2009-09-02 2012-07-11 Access Business Group International LLC Composition and method for skin repair
WO2011079212A2 (en) * 2009-12-24 2011-06-30 LifeSpan Extension, LLC Methods and compositions for identifying, producing and using plant-derived products modulating cell function and aging
WO2012177556A2 (en) 2011-06-20 2012-12-27 H.J. Heinz Company Probiotic compositions and methods
CN103027879A (zh) * 2011-09-29 2013-04-10 庞来祥 一种具有保湿作用的枸杞唇膏及其制备方法
PL2844083T3 (pl) 2012-04-23 2018-12-31 University Of Oslo Zastosowanie ekstraktu pomidorowego jako środka przeciwdziałającego nadciśnieniu i proces do sporządzania rozpuszczalnego w wodzie ekstraktu pomidorowego bez cukru
GB201223365D0 (en) * 2012-12-24 2013-02-06 Provexis Natural Products Ltd Compositions
CN105997774A (zh) * 2016-05-10 2016-10-12 芜湖亮晶晶生物科技有限公司 一种止血消炎牙膏及其制备方法
MX2019005054A (es) 2016-11-02 2019-06-20 Provexis Natural Products Ltd Extracto de jitomate soluble en agua protege contra los efectos adversos de la contaminacion del aire.
CN106667937B (zh) * 2017-01-03 2020-01-17 河北省农林科学院经济作物研究所 一种黑枸杞多糖咀嚼片
TWI727584B (zh) 2019-06-20 2021-05-11 財團法人工業技術研究院 抑制皮膚細胞增生及/或抗發炎之組成物以及芹菜素與木犀草素在製備抑制皮膚細胞增生及/或抗發炎之組成物的用途
CN110742883A (zh) * 2019-12-05 2020-02-04 华南农业大学 二氢杨梅素在缓解呕吐毒素引起肠道细胞损伤中的应用
CN112022767B (zh) * 2020-09-17 2023-04-07 云南省药物研究所 一种抗炎抑菌增强免疫祛痘组合物及其应用
MX2024007249A (es) * 2021-12-20 2024-07-10 Nestle Sa Proceso para preparar una composicion de bayas.
CN114209810B (zh) * 2022-01-06 2023-02-07 宁夏杞肽科技有限公司 枸杞糖肽在制备用于预防或治疗炎性肠病的药物中的用途
JP7587294B2 (ja) * 2022-04-01 2024-11-20 丸善製薬株式会社 正常ヒト歯肉線維芽細胞におけるｉ型コラーゲン産生促進剤及び口腔用剤
CN118662572A (zh) * 2024-05-31 2024-09-20 北京工商大学 一种具有延缓皮肤光老化和抑制炎症功效的中华枸杞水提物制备与应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1100949A (zh) * 1994-03-11 1995-04-05 李启才 金樱保健系列产品及其制法
CN1135338A (zh) * 1995-05-06 1996-11-13 孙秀英 芸杞保健茶
CN1296757A (zh) * 2000-07-09 2001-05-30 鄂来明 芦荟奶制品
KR101147947B1 (ko) * 2001-12-28 2012-05-29 산토리 홀딩스 가부시키가이샤 ２?Ｏ?（β?Ｄ?글루코피라노실）아스코르브산, 그의 제조, 및 이를 함유하는 조성물 포함 식품 및 화장품
RU2302879C2 (ru) * 2002-04-09 2007-07-20 Сычуан Институте Оф Чайниз Материа Медика Фармацевтическая композиция для лечения ревматизма, способ ее приготовления и применение
CN100594919C (zh) * 2002-11-08 2010-03-24 汪建平 含有枸杞提取活性物质的药物组合物及其应用
WO2005018656A1 (ja) * 2003-08-21 2005-03-03 Kaneka Corporation 脳神経細胞死予防及び／または改善剤
CN1913888A (zh) * 2003-12-18 2007-02-14 荷兰联合利华有限公司 降低应激对皮肤调理的作用的方法
MY142017A (en) * 2004-03-19 2010-08-16 Nestec Sa Composition comprising all essential nutrients of a fruit or a plant material with increased stability and bioavailability and process of forming the same
US20060024339A1 (en) * 2004-07-29 2006-02-02 Howard Murad Methods of managing the redness associated with a dermatological condition
US7776915B2 (en) * 2005-03-24 2010-08-17 Tracie Martyn International, Llc Topical formulations and methods of use
JP2007176814A (ja) * 2005-12-27 2007-07-12 Yoshihiro Futamura 炎症性サイトカイン産生抑制作用を有するゼアキサンチン誘導体、それからなる食品製剤、化粧品、抗炎症剤

Also Published As

Publication number Publication date
EP2200623A1 (en) 2010-06-30
CN101795699A (zh) 2010-08-04
EP2200624B1 (en) 2018-09-05
CA2699233A1 (en) 2009-03-19
BRPI0816789A2 (pt) 2015-03-17
US20100221372A1 (en) 2010-09-02
MX2010002499A (es) 2010-04-27
CA2698860A1 (en) 2009-03-19
ES2698199T3 (es) 2019-02-01
TW200930389A (en) 2009-07-16
CN103417728A (zh) 2013-12-04
CA2699233C (en) 2019-03-19
JP2010540415A (ja) 2010-12-24
PT2200624T (pt) 2018-11-29
EP2200624A1 (en) 2010-06-30
AR068448A1 (es) 2009-11-18
RU2499604C2 (ru) 2013-11-27
US9072769B2 (en) 2015-07-07
WO2009034165A1 (en) 2009-03-19
US20100303741A1 (en) 2010-12-02
EP2036568A1 (en) 2009-03-18
HK1146229A1 (en) 2011-05-20
RU2010114192A (ru) 2011-10-20
AU2008297074A1 (en) 2009-03-19
CN101795699B (zh) 2013-07-10
WO2009034162A1 (en) 2009-03-19

Similar Documents

Publication Publication Date Title
CL2008002692A1 (es) Uso de una composicion a base de bayas de goji o una parte de la misma para preparar un producto util para tratar o prevenir la inflamacion.
PH12017500930A1 (en) Hsp90 inhibitor combinations
CL2008001633A1 (es) Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
CL2008002042A1 (es) Compuestos derivados de heterociclos nitrogenados enlazados; y su uso en el tratamiento de la diabetes y desordenes metabolicos.
BRPI0716210A2 (pt) Métodos, composições e aparelhos para tratar feridas com pressões diferentes da atmosférica
CL2007002384A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis.
MX2009009292A (es) Compuestos activos en ppar.
MX2009001327A (es) Compuestos de indol.
MX2014011134A (es) Compuestos de carbamato y preparacion y uso de los mismos.
CL2016001231A1 (es) Compuestos de inhibidor de autotaxina
MX349796B (es) Composiciones farmacéuticas para usarse en el tratamiento de trastornos oncológicos mediante el uso de coenzima q10.
EA201390609A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
BRPI0818366A2 (pt) Composto, pró-droga, medicamento, método inibidor de faah, métodos de profilaxia ou tratamento para ansiedade, ou depressão, ou de alívio da dor, e de profilaxia ou tratamento para dor inflamatória ou dor neuropática, e, uso do composto.
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
EA201000888A1 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и 2-фенилциклогексан-1,3,5-трионы в качестве гербицидов
BRPI0922233A2 (pt) compostos, composições farmacêiticas e métodos para uso no tratamento de síndromes metabólicas.
BRPI0914371A2 (pt) "composto, composição farmacêutica, uso de um composto, método para tratar um indivíduo, e produto de combinação"
CL2008003265A1 (es) Compuestos derivados de heterociclos nitrogenados, supresores de la produccion de colageno; composicion farmaceutica que comprende dichos compuestos; y su uso para prevenir y/o tratar la fibrosis y/o los tumores.
BRPI0912539A2 (pt) composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
BRPI0816255A2 (pt) Produto farmacêutico, uso do produto, método para a profilaxia ou o tratamento de doenças, e, composição farmaceuticamente aceitável
BRPI0911203A2 (pt) peptídeo ou derivado de peptídeo, composição farmacêutica, uso de um peptídeo ou derivado de peptídeo, métodos para tratar um paciente tendo uma deficiencia e para preparar o peptídeo ou derivado de peptídeo.
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.
WO2012158672A3 (en) Compounds for use in treatment of mucositis
BRPI0818323A2 (pt) composição farmacêutica, uso de uma composição farmacêutica, e, método para tratar câncer.
BRPI0818267A2 (pt) Novos derivados de 1,3-dihidro-5-isobenzofuranocarbonitrila e composição farmacêutica dos mesmos para o tratamento de ejaculação precoce